Program
leuprolide mesylate
Also written as “Leuprolide Mesylate” and “Leuprolide Injectable Emulsion (CAMCEVI®)”.
Its studies are mostly in Prostatic Neoplasms, led by 2 companies.
Drug pageLeuprolide mesylate: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Foresee Pharmaceuticalsits history only | 20 open or running | phase 3since Sep 1, 2014 | Sep 1, 2014 | none ahead |
| Changchun GeneScience Pharmaceutical | 10 open or running | phase 3since May 11, 2025 | May 11, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Changchun GeneScience Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 11, 2025First study: phase 3 study in Advanced Prostate CancerFirst studyNCT06984159 · 137 enrolled · China
TargetBeta
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on GNRHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Leuproliderule | Takeda | phase 4 | 39 |
| triptorelinrule | Ipsen | phase 4 | 21 |
| Goserelinrule | AstraZeneca | phase 4 | 14 |
| linzagolixrule | Kissei Pharmaceutical | phase 3 | 14 |
| GnRH Antagonist SHR7280 | Jiangsu HengRui Medicine | phase 3 | 10 |
| Gonadotropin-Releasing Hormonerule | Ferring Pharmaceuticals | phase 3 | 5 |
Studies
The one study Changchun GeneScience Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06984159Advanced Prostate Cancer · China | 3 | Completed | Nov 30, 2023 | 137 |
How it is read
Names in the registry
- “Leuprolide Mesylate”, 2 entries
- “Leuprolide Injectable Emulsion (CAMCEVI®)”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.